Compare LENZ & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LENZ | ELTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.8M | 185.4M |
| IPO Year | 2021 | 2014 |
| Metric | LENZ | ELTX |
|---|---|---|
| Price | $5.57 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $44.00 | $18.00 |
| AVG Volume (30 Days) | 610.6K | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | $2,301,000.00 |
| Revenue This Year | $50.42 | N/A |
| Revenue Next Year | $197.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.73 | $2.66 |
| 52 Week High | $50.19 | $16.00 |
| Indicator | LENZ | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.32 | 32.52 |
| Support Level | N/A | $2.66 |
| Resistance Level | $10.42 | $9.95 |
| Average True Range (ATR) | 0.43 | 1.43 |
| MACD | -0.05 | -0.94 |
| Stochastic Oscillator | 0.56 | 9.60 |
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.